MarginsXMarginsX
Home › Markets › CLVLF

Clinuvel Pharmaceuticals Ltd (CLVLF)

CLVLF is quoted over the counter, not listed on an exchange. Clinuvel Pharmaceuticals Ltd files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.

Last trade · October 30, 2026
$4.95
No trades since Oct 30, 2026; later closes repeat the last quote
1-year return
-34.5%
Market cap
The company also trades on Nasdaq as CUVL; this OTC line is another class or a foreign line, so its cap is not computed
P/E and P/S
Needs a market cap · Needs a market cap
On fiscal year to June 30, 2026 (20-F)

Closes: Yahoo Finance daily closes, last bar 2026-11-13.

Profile

FieldValue
TickerCLVLF, quoted over the counter
SEC CIK0001290877
OTC Markets tierPink (price source, 2026-11-13)
SEC industry codeAmerican Depositary Receipts
Business addressMelbourne, Victoria
Incorporated inAustralia

Warning signs

Cash runway
Cash-flow positive
$13.9M cash at June 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
20-F filed October 30, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-10-30
Cash and burn$13.9M cash; operating cash flow $3.2M a quarter.Report 2026-06-30
Shares outstanding50,427,898 (2026-06-30).Cover page 2026-06-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton Audit Pty Ltd, Melbourne, AustraliaPCAOB Form AP 2026-07-08
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-06-30
$64.3M$23.2M$12.9M$13.9MNo debt tags$64.3M20-F 2026-10-30
FY 2025
2025-06-30
$61.1M$23.1M$27.3M$18.1MNo debt tags$61.1M20-F 2026-10-30
FY 2024
2024-06-30
$57.9M$23.3M$23.8MNot filedNo debt tags$57.9M20-F 2026-10-30

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-07-17
Latest annual report20-F2026-10-30
Latest quarterly / interim6-K2026-10-30

Source: SEC EDGAR submissions feed, 49 recent filings. All filings on EDGAR.

The full dossier has every filing, quarterly and annual financials, the health record and a price chart.

Open the full dossier